This content is from: Home

Davis Polk advises AstraZeneca on $15b spin-off and merger

Pharmaceuticals business AstraZeneca has chosen the same lawyers that worked on its recent merger to advise on the company's next step, a deal valued at $15 billion.

To access our in-house intelligence please request a trial here.

Read this article – and more – for a one-week period.

REQUEST ACCESS

Are you already an IFLR subscriber? Login here

Instant access to all of our content. Membership Options | One Week Trial